Oral insulin does not alter gut microbiota composition of NOD mice

Diabetes/Metabolism Research and Reviews

Volumn 34, Issue 6, 2018, Pages

  Kihl, Pernille ^a   Krych, Lukasz ^a   Buschard, Karsten ^b   Wesley, Johnna D ^d   Kot, Witold ^c   Hansen, Axel Kornerup ^a   Nielsen, Dennis S ^a   von Herrath, Matthias G ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d NOVO NORDISK INC   (United States)

Author keywords

insulin; microbiota; NOD; oral; type 1 diabetes

Indexed keywords

PIG INSULIN;

AKKERMANSIA MUCINIPHILA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; FLOW CYTOMETRY; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; MORNING DOSAGE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; ANIMAL; DRUG EFFECT; DYSBIOSIS; EXPERIMENTAL DIABETES MELLITUS; FECES; IMMUNOLOGY; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PIG;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DYSBIOSIS; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; INSULIN, REGULAR, PORK; MICE; MICE, INBRED NOD; SWINE;

EID: 85046119879     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.3010     Document Type: Article

References (58)

1. Wilcox NS, Rui J, Hebrok M, Herold KC. Life and death of β cells in type 1 diabetes: a comprehensive review. J Autoimmun. 2016;71:51-58.
2. Atkinson MA. The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2:a007641.
3. Dotta F, Censini S, van Halteren AGS, et al. Coxsackie B4 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci. 2007;104(12):5115-5120.
4. Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes. Pros and Cons. 2008;57:2863-2871.
5. Buschard K. What causes type 1 diabetes? Lessons from animal models. APMIS. 2011;119(1):1-19.
6. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41(6):703-707.
7. Nielsen DS, Krych Ł, Buschard K, Hansen CHF, Hansen AK. Beyond genetics. Influence of dietary factors and gut microbiota on type 1 diabetes. FEBS Lett. 2014;588(22):4234-4243.
8. Vatanen T, Kostic Aleksandar D, d'Hennezel E, et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell. 2016;165(4):842-853.
9. Qi CJ, Zhang Q, Yu M, et al. Imbalance of fecal microbiota at newly diagnosed type 1 diabetes in Chinese children. Chin Med J (Engl). 2016;129(11):1298-1304.
10. Vaarala O, Atkinson MA, Neu J. The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes. 2008;57(10):2555-2562.
11. Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature. 2008;455:1109-1U10.
12. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet. 2014;383(9911):69-82.
13. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. The Lancet. 357(9253):331-335.
14. Fonte P, Araújo F, Reis S, Sarmento B. Oral insulin delivery: how far are we? J Diabetes Sci Technol. 2013;7(2):520-531.
15. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S a. 1991;88(22):10252-10256.
16. Grant CW, Moran-Paul CM, Duclos SK, Guberski DL, Arreaza-Rubín G, Spain LM. Testing agents for prevention or reversal of type 1 diabetes in rodents. PloS one. 2013;8(8):e72989.
17. Homann D, Dyrberg T, Petersen J, Oldstone MB, von Herrath MG. Insulin in oral immune “tolerance”: a one-amino acid change in the B chain makes the difference. Journal of immunology Baltimore, Md : 1950. 1999;163:1833-1838.
18. Greenbaum C. Oral Insulin Prevention Study. https://wwwtrialnetorg/our-research/completed-studies/oralinsulin. 2017.
19. Zijlstra E, Heinemann L, Plum-Mörschel L. Oral insulin reloaded: a structured approach. J Diabetes Sci Technol. 2014;8(3):458-465.
20. Rekers NV, von Herrath MG, Wesley JD. Immunotherapies and immune biomarkers in type 1 diabetes: a partnership for success. Clin Immunol. 2015;161(1):37-43.
21. Gordon Still J. Development of oral insulin: progress and current status. Diabetes Metab Res Rev. 2002;18(S1):S29-S37.
22. Saffran M. Oral administration of insulin: imitating the natural pathway. In: Gregoriadis G, Florence AT, Poste G, eds. Targeting of Drugs 3: The Challenge of Peptides and Proteins. Boston, MA: Springer US; 1992:89-95.
23. Pham MN, Gibson C, Ryden AK, et al. Oral insulin (human, murine, or porcine) does not prevent diabetes in the non-obese diabetic mouse. Clinical immunology Orlando, Fla. 2016;164:28-33.
24. Gronholm J, Pagni PP, Pham MN, et al. Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice. Diabetologia. 2017;60(8):1475-1482.
25. Busko M. Oral insulin may delay type 1 diabetes onset in ‘responders’ Medscape Jun 23, 2017.
26. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res. 2007;24(12):2198-2206.
27. Health USNIo. clinicaltrials.gov.
28. Arbit E, Kidron M. Oral insulin delivery in a physiologic context: review. J Diabetes Sci Technol. 2017;11(4):825-832.
29. Hartmann B, Bellmann K, Ghiea I, Kleemann R, Kolb H. Oral insulin for diabetes prevention in NOD mice: potentiation by enhancing Th2 cytokine expression in the gut through bacterial adjuvant. Diabetologia. 1997;40(8):902-909.
30. Matteucci E, Giampietro O, Covolan V, Giustarini D, Fanti P, Rossi R. Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery. Drug Des Devel Ther. 2015;9:3109-3118.
31. Sonaje K, Lin KJ, Wey SP, et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials. 2010;31(26):6849-6858.
32. Montandon S, Jornayvaz F. Effects of antidiabetic drugs on gut microbiota composition. Genes. 2017;8(10):250.
33. Zhang X, Zhao Y, Xu J, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep. 2015;5(1):14405.
34. Wang L, Li P, Tang Z, Yan X, Feng B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci Rep. 2016;6(1):33251.
35. Goodacre R. Metabolomics of a superorganism. J Nutr. 2007;137(1):259s-266s.
36. Kamada N, Seo SU, Chen GY, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321-335.
37. Joyce SA, Gahan CG. Disease-associated changes in bile acid profiles and links to altered gut microbiota. Digestive Diseases (Basel, Switzerland). 2017;35(3):169-177.
38. Ejsing-Dunn M, Josephsen J, Aasted B, Buschard K, Hansen AK. Dietary gluten reduces the number of intestinal regulatory T-cells in mice. Scand J Immunol. 2008;67(6):553-559.
39. Hansen AK, Ling F, Kaas A, Funda DP, Farlov H, Buschard K. Diabetes preventive gluten-free diet decreases the number of caecal bacteria in non-obese diabetic mice. Diabetes Metab Res Rev. 2006;22(3):220-225.
40. Hansen CHF, Krych L, Buschard K, Metzdorff SB, Nellemand CN, Hansen LH, Nielsen DS, Frøkiær H, Skov S and Hansen AK. A maternal gluten free diet reduces inflammation and diabetes incidence in the offspring of NOD mice. Diabetes. 2014;Accepted for publication.
41. Funda DP, Kaas A, Bock H, Tlaskalova-Hogenova H, Buschard K. Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev. 1999;15(5):323-327.
42. Zachariassen LF, Krych L, Engkilde K, et al. Sensitivity to oxazolone induced dermatitis is transferable with gut microbiota in mice. Sci Rep. 2017;7:44385.
43. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Meth. 2013;10(10):996-998.
44. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012;6(3):610-618.
45. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335-336.
46. Mandal S, Van Treuren W, White RA, Eggesbø M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microbial Ecology in Health and Disease. 2015;26:https://doi.org/10.3402/mehd.v26.27663(0).
47. Rose S, Misharin A, Perlman H. A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment. Cytometry Part a : The Journal of the International Society for Analytical Cytology. 2012;81(4):343-350.
48. Antvorskov JC, Fundova P, Buschard K, Funda DP. Dietary gluten alters the balance of proinflammatory and anti-inflammatory cytokines in T cells of BALB/c mice. Immunology. 2012;138:23-33.
49. Funda DP, Kaas A, Tlaskalova-Hogenova H, Buschard K. Gluten-free but also gluten-enriched (gluten+) diet prevent diabetes in NOD mice; the gluten enigma in type 1 diabetes. Diabetes Metab Res Rev. 2008;24(1):59-63.
50. Wilson ID, Nicholson JK. The role of gut microbiota in drug response. Curr Pharm Des. 2009;15(13):1519-1523.
51. Lindenbaum J, Rund DG, Butler VPJ, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut Flora: reversal by antibiotic therapy. New England Journal of Medicine. 1981;305(14):789-794.
52. Ney DM, Murali SG, Stroup BM, et al. Metabolomic changes demonstrate reduced bioavailability of tyrosine and altered metabolism of tryptophan via the kynurenine pathway with ingestion of medical foods in phenylketonuria. Mol Genet Metab. 2017;121(2):96-103.
53. Bosi E, Molteni L, Radaelli MG, et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia. 2006;49(12):2824-2827.
54. Round JL, Mazmanian SK. The gut microbiome shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313-323.
55. Ahern P-á, Faith J-á, Gordon J-á. Mining the human gut microbiota for effector strains that shape the immune system. Immunity. 40(6):815-823.
56. B+ñckhed F. Host responses to the human microbiome. Nutr Rev. 2012;70:S14-S17.
57. Bangsgaard Bendtsen KM, Krych L, S+©rensen DB, et al. Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse. PloS one. 2012;7(10):e46231.
58. Bisgaard H, Li N, Bonnelykke K, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol. 2011;128(3):646-652.